These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 31011328)

  • 1. Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer's Disease in Amnestic Mild Cognitive Impairment.
    Park JE; Choi KY; Kim BC; Choi SM; Song MK; Lee JJ; Kim J; Song HC; Kim HW; Ha JM; Seo EH; Song WK; Park SG; Lee JS; Lee KH
    Dement Geriatr Cogn Dis Extra; 2019; 9(1):100-113. PubMed ID: 31011328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study.
    Lauridsen C; Sando SB; Shabnam A; Møller I; Berge G; Grøntvedt GR; Bakken IJ; Salvesen Ø; Bråthen G; White LR
    Front Aging Neurosci; 2016; 8():30. PubMed ID: 26973507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
    Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
    J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
    Engelborghs S
    Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.
    Somers C; Struyfs H; Goossens J; Niemantsverdriet E; Luyckx J; De Roeck N; De Roeck E; De Vil B; Cras P; Martin JJ; De Deyn PP; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2016 Aug; 54(1):383-95. PubMed ID: 27567807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer's Disease Spectrum with Amyloid PET Imaging.
    Lim HJ; Park JE; Kim BC; Choi SM; Song MK; Cho SH; Seo HJ; Kim J; Song HC; Choi KY; Lee JJ; Kim HW; Ha JM; Song WK; Park SG; Lee JS; Lee KH
    J Alzheimers Dis; 2020; 75(3):949-958. PubMed ID: 32390627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive impairment in remitted late-life depression is not associated with Alzheimer's disease-related CSF biomarkers.
    Loureiro JC; Stella F; Pais MV; Radanovic M; Canineu PR; Joaquim HPG; Talib LL; Forlenza OV
    J Affect Disord; 2020 Jul; 272():409-416. PubMed ID: 32553384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia.
    Forlenza OV; Radanovic M; Talib LL; Aprahamian I; Diniz BS; Zetterberg H; Gattaz WF
    Alzheimers Dement (Amst); 2015 Dec; 1(4):455-63. PubMed ID: 27239524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
    Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
    Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of combined CSF biomarkers in AD diagnosis.
    De Riva V; Galloni E; Marcon M; Di Dionisio L; Deluca C; Meligrana L; Bolner A; Perini F
    Clin Lab; 2014; 60(4):629-34. PubMed ID: 24779297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker positive and negative subjects in the ADNI cohort: clinical characterization.
    Kennedy RE; Schneider LS; Cutter GR;
    Curr Alzheimer Res; 2012 Dec; 9(10):1135-41. PubMed ID: 22963265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
    Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L
    Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis.
    Stefani A; Bernardini S; Panella M; Pierantozzi M; Nuccetelli M; Koch G; Urbani A; Giordano A; Martorana A; Orlacchio A; Federici G; Bernardi G
    J Neurol Sci; 2005 Oct; 237(1-2):83-8. PubMed ID: 15990115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis.
    Struyfs H; Niemantsverdriet E; Goossens J; Fransen E; Martin JJ; De Deyn PP; Engelborghs S
    Front Neurol; 2015; 6():138. PubMed ID: 26136723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Machine Learning Reveals a Multipredictor Nomogram for Diagnosing the Alzheimer's Disease Based on Chemiluminescence Immunoassay for Total Tau in Plasma.
    Zhang L; Wang D; Dai Y; Wang X; Cao Y; Liu W; Tao Z
    Front Aging Neurosci; 2022; 14():863673. PubMed ID: 35645782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
    Fagan AM; Shaw LM; Xiong C; Vanderstichele H; Mintun MA; Trojanowski JQ; Coart E; Morris JC; Holtzman DM
    Arch Neurol; 2011 Sep; 68(9):1137-44. PubMed ID: 21555603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine.
    Chiasserini D; Biscetti L; Farotti L; Eusebi P; Salvadori N; Lisetti V; Baschieri F; Chipi E; Frattini G; Stoops E; Vanderstichele H; Calabresi P; Parnetti L
    J Alzheimers Dis; 2016 Jul; 54(1):55-67. PubMed ID: 27447425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ
    Duron E; Vidal JS; Grousselle D; Gabelle A; Lehmann S; Pasquier F; Bombois S; Buée L; Allinquant B; Schraen-Maschke S; Baret C; Rigaud AS; Hanon O; Epelbaum J
    Front Aging Neurosci; 2018; 10():297. PubMed ID: 30327597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.